Compare Enveric Biosciences Inc (ENVB) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Orion Office REIT Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Orion Office REIT Inc trades at $2.19 (market cap $125.50M). The key difference: Orion Office REIT Inc is far larger — about 18.5× Enveric Biosciences Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Orion Office REIT Inc for 33 Days on average.
| ENVB | ONL | |
|---|---|---|
Market Cap | $6.80M | $125.50M |
Volume | 64,867 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $10.80 | $3.00 |
52-Week Low | $1.27 | $1.93 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | -$1.49M | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
ONL trades at $2.27, down 2.58% today, with a bearish technical signal from moving averages but bullish oscillators. The company shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Analyst consensus is split 50/50 buy/hold, while recent news highlights strategic portfolio repositioning and Q2 2026 earnings beat.
Outlook remains challenged by negative profitability and high debt levels, though low P/B of 0.2 suggests deep value. Key risks include office sector headwinds and cash flow volatility. Investment appeal hinges on successful execution of turnaround strategy amid weak fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
